EGFR and neoplasm: In Western countries, EGFR mutations are present in 10–35% of NSCLC cases, but the prevalence of these mutations is not uniform among populations; it tends to be more prevalent in females, non-smokers, and patients with bronchioloalveolar features in tumor specimens [8,9,10].